Alpine Immune Sciences Inc (NASDAQ:ALPN) has been assigned an average rating of “Buy” from the seven brokerages that are presently covering the company, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $12.80.
Several analysts recently issued reports on the company. Zacks Investment Research lowered Alpine Immune Sciences from a “buy” rating to a “hold” rating in a report on Thursday, March 21st. Oppenheimer set a $13.00 price objective on Alpine Immune Sciences and gave the stock a “buy” rating in a report on Tuesday, March 19th. ValuEngine upgraded Alpine Immune Sciences from a “sell” rating to a “hold” rating in a report on Tuesday, March 5th. Finally, restated a “buy” rating and set a $13.00 target price on shares of Alpine Immune Sciences in a report on Tuesday, February 12th.
A number of hedge funds and other institutional investors have recently bought and sold shares of ALPN. Northern Trust Corp bought a new position in Alpine Immune Sciences during the first quarter valued at about $71,000. Raymond James & Associates bought a new position in Alpine Immune Sciences during the first quarter valued at about $94,000. Dimensional Fund Advisors LP raised its holdings in Alpine Immune Sciences by 9.4% during the first quarter. Dimensional Fund Advisors LP now owns 41,667 shares of the biotechnology company’s stock valued at $286,000 after buying an additional 3,578 shares in the last quarter. Hikari Power Ltd bought a new position in Alpine Immune Sciences during the fourth quarter valued at about $453,000. Finally, Victory Capital Management Inc. raised its holdings in Alpine Immune Sciences by 109.0% during the fourth quarter. Victory Capital Management Inc. now owns 136,072 shares of the biotechnology company’s stock valued at $501,000 after buying an additional 70,980 shares in the last quarter. Institutional investors own 53.99% of the company’s stock.
Shares of NASDAQ:ALPN opened at $5.62 on Friday. The company has a quick ratio of 7.33, a current ratio of 7.33 and a debt-to-equity ratio of 0.03. Alpine Immune Sciences has a 1 year low of $3.66 and a 1 year high of $9.55. The firm has a market cap of $104.37 million, a P/E ratio of -2.14 and a beta of 2.06.
Alpine Immune Sciences (NASDAQ:ALPN) last announced its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($0.70) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.69) by ($0.01). Analysts anticipate that Alpine Immune Sciences will post -2.67 earnings per share for the current year.
Alpine Immune Sciences Company Profile
Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202, a programmed cell death protein ligand 1 (PD-L1)/cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antagonist with PD-L1 dependent CD28 costimulation for the treatment of cancer.
Recommended Story: What is a good rate of return for a mutual fund?
Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.